| Kyle Micheal Lewis, MD | |
|
25 Michigan St Ne, Suite 2200, Grand Rapids, MI 49503-2515 | |
| (616) 391-3245 | |
| (616) 391-3130 |
| Full Name | Kyle Micheal Lewis |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 25 Michigan St Ne, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295099174 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301101548 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Chester Hospital | West chester, OH | Hospital |
| University Of Cincinnati Medical Center, Llc | Cincinnati, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Cincinnati Physicians Company Llc | 2264344480 | 1339 |
News Archive
Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.
The Swedish biotech company Karo Bio today announced that results from a clinical phase II study of the company's thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
› Verified 1 days ago
| Entity Name | University Of Cincinnati Physicians Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801840434 PECOS PAC ID: 2264344480 Enrollment ID: O20031105000123 |
News Archive
Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.
The Swedish biotech company Karo Bio today announced that results from a clinical phase II study of the company's thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyle Micheal Lewis, MD Po Box 636256 Central Credentialing, Cincinnati, OH 45263-6256 Ph: (513) 245-3107 | Kyle Micheal Lewis, MD 25 Michigan St Ne, Suite 2200, Grand Rapids, MI 49503-2515 Ph: (616) 391-3245 |
News Archive
Correlogic Systems, Inc. announced today that OvaCheck, the company's blood test for the detection of epithelial ovarian cancer, has fulfilled European Union regulatory requirements (CE marking) for distribution and sale of the test. The path is now cleared for the test to be made available to patients in Europe through their physicians.
The Swedish biotech company Karo Bio today announced that results from a clinical phase II study of the company's thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.
The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.
Much of the devastation of stroke and head trauma is due to damage caused the overproduction of a substance in the brain called glutamate. Preventing this damage has been impossible, until now, as many drugs don't cross the so-called blood-brain barrier, and those that do often don't work as intended. But a method originally devised at the Weizmann Institute of Science may, in the future, offer a way to avert such glutamate-induced harm.
The U.S. Food and Drug Administration today issued guidance on Bayesian statistical methods in the design and analysis of medical device clinical trials that could result in less costly and more efficient patient studies.
› Verified 1 days ago
Dr. Jon R Henke, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Geoffrey M. Remes, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Jan L Mourelatos, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-361-5828 | |
Dr. Brendan Michael Banyon, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 | |
Dr. Joseph J Junewick, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7272 Fax: 616-363-7290 | |
Keith Alan Morrow, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 Fax: 616-361-5828 | |
Dr. Andrew Kent Moriarity, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3264 N Evergreen Dr Ne, Grand Rapids, MI 49525 Phone: 616-363-7339 |